What happened: STAT News reports that the FDA appears open to Moderna’s flu vaccine heading into an advisory committee meeting, a sign of potential momentum for the mRNA program. The publication also noted that UniQure intends to submit its Huntington’s disease therapy for approval, while Eli Lilly has acquired 4E Therapeutics. As of June 18, Moderna’s SEC Form 4 filings through May and June confirm insider transactions, with no new corporate filings tied to approvals or partnerships.
Why it matters: The FDA’s tentative openness suggests Moderna may be preparing to extend its mRNA platform beyond COVID-19, an important, if measured, diversification move for the company’s vaccine portfolio. Should the advisory committee’s tone prove favorable, it could validate mRNA’s broader role in seasonal respiratory vaccines. That might start to pull mRNA flu candidates into a field still ruled by egg-based incumbents. The prevailing read: regulators see Moderna’s flu data as approaching conventional efficacy standards, closing the gap between next-generation and legacy approaches.
For UniQure, the Huntington’s submission effort shows confidence in a notoriously difficult indication, one where gene therapy has long wrestled with durability and safety. Acceptance of such a filing could represent an early regulatory test of sustained CNS gene delivery. Lilly’s purchase of 4E Therapeutics, meanwhile, folds another neuroscience prospect into its growing neurology portfolio. The move underlines continued interest in early innovation even after high-profile CNS disappointments. Altogether, these signals point to an early-summer tilt toward neurological and vaccine assets, as biopharma adjusts its post-pandemic storylines. Then again, this stage might just be the setup.
